The higher anti- proliferative activity of abemaciclib in HR+ cells is consistent with known alterations in many of these cell lines, wherein CCND1 amplification indicates that HR+ breast cancers may be especially reliant on this pathway for tumorigenesis [27]. Here, CCND1 is linked to breast carcinoma.